Fulcrum Therapeutics (FULC) Gains from Sales and Divestitures (2019 - 2026)
Fulcrum Therapeutics (FULC) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $19505.0 as the latest value for Q4 2025.
- Quarterly Gains from Sales and Divestitures fell 12.64% to $19505.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19505.0 through Dec 2025, down 12.64% year-over-year, with the annual reading at $19505.0 for FY2025, 12.64% down from the prior year.
- Gains from Sales and Divestitures for Q4 2025 was $19505.0 at Fulcrum Therapeutics, roughly flat from $19505.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $47706.0 in Q2 2021, with the low at $5496.0 in Q1 2023.
- Average Gains from Sales and Divestitures over 5 years is $21556.7, with a median of $19505.0 recorded in 2025.
- The sharpest move saw Gains from Sales and Divestitures plummeted 85.31% in 2021, then skyrocketed 110.15% in 2024.
- Over 5 years, Gains from Sales and Divestitures stood at $42858.0 in 2021, then crashed by 76.26% to $10174.0 in 2022, then surged by 78.34% to $18144.0 in 2023, then grew by 23.05% to $22326.0 in 2024, then dropped by 12.64% to $19505.0 in 2025.
- According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $19505.0, $19505.0, and $19505.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.